8-K: Neuronetics Announces Preliminary 2024 Results and Issues Optimistic 2025 Guidance Following Greenbrook Acquisition

Neuronetics reports preliminary 2024 revenue and provides 2025 guidance, highlighting the impact of the Greenbrook TMS acquisition and expected profitability by Q3 2025.

Summary

• Neuronetics announced preliminary unaudited revenue of $22.1 million for the fourth quarter of 2024 and $74.5 million for the full year.
• The company completed the acquisition of Greenbrook TMS on December 9, 2024.
• Neuronetics expects pro forma year-over-year revenue growth of 12% to 19% for 2025.
• The company anticipates realizing over $22 million in annualized cost synergies.
• Neuronetics projects achieving cash flow breakeven in the third quarter of 2025.
• The company shipped 50 systems in the fourth quarter of 2024.
• The Better Me Provider program has over 350 active sites and over 125 more committed to joining.
• The FDA cleared NeuroStar Advanced Therapy as a first-line add-on treatment for adolescents with depression in March 2024.
• This FDA clearance increased the total addressable market for MDD by approximately 35% to 29.3 million patients.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with strong growth projections, cost synergies, and a clear path to profitability. The acquisition of Greenbrook TMS and FDA clearance for adolescent depression treatment are significant positive developments. However, there are still risks associated with integration and achieving profitability.

Positives

• The acquisition of Greenbrook TMS is expected to drive faster revenue growth and improve the cost structure.
• The company has identified and is implementing significant cost synergies.
• The Better Me Provider program is showing strong results in improving patient care and accessibility.
• The FDA clearance for adolescent depression treatment expands the market significantly.
• The company is projecting to achieve cash flow breakeven in the third quarter of 2025.

Negatives

• The company has a history of losses and needs to achieve and sustain profitable operations.
• The company relies heavily on the sale and use of its NeuroStar system for revenue.
• The company's revenue has been concentrated among a small number of customers.

Risks

• The integration of Greenbrook TMS may impact business relationships and operating results.
• The company's ability to execute its business strategy and achieve profitability is uncertain.
• The company's reliance on the NeuroStar system and a small number of customers poses a risk.
• There are risks related to competition, product defects, and intellectual property protection.
• The company's ability to achieve cash flow break-even in Q3 2025 is not guaranteed.
• The company's self-sustainability and existing cash balances are a risk.

Future Outlook

Neuronetics expects to achieve double-digit revenue growth for the full year 2025 and achieve cash flow breakeven during the third quarter of 2025.

Management Comments

• Keith J. Sullivan, President and Chief Executive Officer of Neuronetics, stated that the acquisition of Greenbrook TMS brings together two leading mental health device companies.
• He also mentioned that the new organization can leverage its combined scale and expertise to deliver faster revenue growth and a significantly improved cost structure, accelerating the path to profitability.
• Management is excited about the future and will continue to expand leadership positions to increase patient access to innovative mental health treatments and drive value for shareholders.

Industry Context

This announcement reflects a trend of consolidation in the mental health device industry, with Neuronetics acquiring Greenbrook TMS to expand its market reach and leverage synergies. The focus on innovative treatments and patient accessibility aligns with broader industry goals.

Comparison to Industry Standards

• Neuronetics' acquisition of Greenbrook TMS is similar to other consolidations in the medical device industry, such as Medtronic's acquisition of Covidien, aiming to achieve economies of scale and expand market presence.
• The projected revenue growth of 12% to 19% is competitive with other medical device companies in the growth phase, such as InMode, which has seen similar growth rates in recent years.
• The focus on cost synergies is a common strategy in post-merger integrations, similar to the cost-cutting measures implemented by companies like Zimmer Biomet after their merger.
• The Better Me Provider program is an attempt to improve patient access and outcomes, similar to initiatives by companies like Teladoc Health to expand telehealth services.
• The FDA clearance for adolescent depression treatment is a significant milestone, giving Neuronetics a competitive advantage over other TMS providers that do not have this indication, such as Brainsway.

Stakeholder Impact

• Shareholders are expected to benefit from the projected revenue growth and profitability.
• Employees may experience changes due to the integration of Greenbrook TMS.
• Patients will have increased access to mental health treatments through the combined network.
• Suppliers may see increased demand due to the company's growth.
• Creditors may have increased confidence in the company's financial stability.

Next Steps

• The company will continue to integrate Greenbrook TMS into its organization.
• Neuronetics will actively execute key growth initiatives to optimize performance.
• The company will continue to expand the Better Me Provider program.
• Neuronetics will provide additional guidance during its fourth quarter earnings call.

Key Dates

Keywords

Neuronetics, Greenbrook TMS, TMS, NeuroStar, Mental Health, Depression, Acquisition, Revenue, Cost Synergies, FDA Clearance, Adolescent Depression, Cash Flow Breakeven